Loading organization details...
Loading organization details...
TO PROVIDE THE HIGHEST QUALITY COMPREHENSIVE CARE FOR PEOPLE WITH KIDNEY DISEASE USING A MULTIFACETED INTEGRATIVE APPROACH THAT EMPHASIZES INNOVATIVE TREATMENT OPTIONS AND EDUCATION.
Source: IRS Form 990 (Tax Year 2024)
Source: IRS e-Filed Form 990 (from the IRS e-File system), Tax Year 2024
Total Revenue
▼$122.8M
Program Spending
80%
of total expenses go to program services
Total Contributions
$5M
Total Expenses
▼$122M
Total Assets
$111.8M
Total Liabilities
▼$95.2M
Net Assets
$16.6M
Officer Compensation
→$2.9M
Other Salaries
$51.9M
Investment Income
$316.3K
Fundraising
▼$0
Tax Year 2024 · Source: IRS Form 990, Schedule I (Grants and Other Assistance)
Total grants awarded: $1.5M
| Recipient | Location | Amount | Type | Purpose |
|---|---|---|---|---|
UT Southwestern Medical Center75-6002868 | Dallas, TX | $1.2M | Cash | SUPPORT |
| Birmingham, AL | $354.6K | Cash | SUPPORT | |
| Total | $1.5M | |||
Dallas, TX
$1.2M
$354.6K
Source: USAspending.gov · Searched by organization name
VA/DoD Awards
$553K
VA/DoD Award Count
1
Funding from the Department of Veterans Affairs and/or Department of Defense.
Total Federal Funding
$15.1M
Awards Found
3
Department of Health and Human Services
$7.6M
APPLICATION OF PROGENITOR NICHE SIGNALS TO EX VIVO NEPHROGENESIS - SPECIFIC AIMS THERE ARE MORE THAN 100K AMERICAN WAITING FOR A KIDNEY TRANSPLANT, BUT DEMAND FAR EXCEEDS SUPPLY. EX VIVO ORGANOGENESIS IS A POTENTIAL SOURCE FOR FUNCTIONAL TISSUE FOR RENAL REPLACEMENT THERAPY. WE AND OTHERS ESTABLISHED TECHNIQUES TO GENERATE CELLULARLY COMPLEX KIDNEY ORGANOIDS FROM HUMAN INDUCED PLURIPOTENT CELLS (IPSCS). THEORETICALLY, IPSC-DERIVED RENAL ORGANOIDS WOULD BE GRAFTED TO HOST TISSUE AND WOULD INTEGRATE WITH VASCULAR AND URINARY SYSTEMS TO SUPPLEMENT LOST KIDNEY FUNCTION. HOWEVER, DATA INDICATES THAT IMPLANTED ORGANOIDS INTEGRATE POORLY WITH THE HOST KIDNEY. BASED ON EXPERIMENTAL OBSERVATIONS, WE IDENTIFIED AT LEAST 3 KEY OBSTACLES THAT MUST BE OVERCOME TO GENERATE INTEGRATED RENAL ORGANOIDS (FIG. 1): TISSUE ORGANIZATION: ORGANOID TUBULES, BLOOD VESSELS, AND STROMA LACK CORTICO-MEDULLARY PATTERN. TUBULAR FUSION: WITH CURRENT STRATEGIES, ORGANOID TUBULES AND VESSELS DO NOT ANASTOMOSE WITH HOST TISSUES. FUNCTIONAL ASSAYS: WE LACK ASSAYS TO IDENTIFY SUCCESSFUL RENAL REPLACEMENT BY ORGANOID TISSUE. THE GOAL OF OUR COLLABORATIVE TEAM IS TO GENERATE THE TOOLS, REAGENTS AND PROTOCOLS TO OVERCOME EACH OF THESE OBSTACLES. IN OUR RECENT STUDIES, WE DISCOVERED THE FOLLOWING: 1) DISTINCT STROMAL CELL POPULATIONS ARE REQUIRED TO ESTABLISH CORRECT ZONAL ORGANIZATION AND SEGMENT-SPECIFIC DIFFERENTIATION OF TUBULES AND VASCULATURE; 2) ORGANOIDS LACK A NORMAL DISTRIBUTION AND COMPLEMENT OF STROMAL CELL POPULATIONS; 3) STROMAL CELLS AND THEIR SECRETED PRODUCTS CAN FACILITATE TUBULE-TUBULE INTERCONNECTION. THESE FINDINGS SHOW THAT FORMATION OF RENAL ORGANOIDS THAT ARE APPROPRIATELY PATTERNED FOR IN VIVO FUNCTION DEPENDS ON CREATING THE CORRECT COMPLEMENT AND ORGANIZATION OF STROMAL CELLS. THE CONCEPT THAT ANATOMICALLY “CORRECT” TISSUE THAT IS MATCHED TO THE ENGRAFTMENT SITE CAN BE GENERATED THROUGH MANIPULATION OF STROMAL CELL POPULATIONS IS NOVEL AND IDENTIFIES A GAP IN OUR UNDERSTANDING OF STROMAL CELL BIOLOGY OF DEVELOPING KIDNEY TISSUE. TO FILL THIS GAP AND GENERATE RESOURCES TO DETERMINE HOW THIS NOVEL PATTERNING MECHANISM CAN BE EXPLOITED TO GENERATE KIDNEY TISSUE FOR RENAL REPLACEMENT, WE PROPOSE A SERIES OF HYPOTHESIS-GENERATING INVESTIGATIONS THAT WILL DEFINE THE ROLES OF DIVERSE STROMAL CELLS IN PATTERNING THE VASCULATURE AND RENAL EPITHELIUM AS WELL AS PROMOTING TUBULAR CONNECTION TO THE HOST. OUR LONGTERM GOAL IS TO GENERATE FUNCTIONAL PROXIMAL NEPHRONS WITH APPROPRIATELY PATTERNED MICROVASCULATURE THAT INTEGRATE WITH THE HOST URINARY AND CIRCULATORY SYSTEMS FOR FUNCTIONAL RENAL REPLACEMENT. TO FACILITATE OUR EFFORTS TO PROMOTE TUBULE AND VASCULAR FUSION, WE WILL DEVELOP A PIPELINE FOR IN VIVO TESTING OF LABORATORY-DERIVED TISSUE IN ANIMALS WITH IMPAIRED KIDNEY FUNCTION. IN PRELIMINARY DATA, WE DEMONSTRATE NOVEL FUNCTIONAL ASSAYS INCLUDING ELISAS AND LIVE IMAGING OF TUBULAR FLUID FLOW THAT CAN RAPIDLY AND EASILY ASSESS THE CONTRIBUTION OF IMPLANTED ORGANOIDS TO HOST URINE PRODUCTION. WE WILL ALSO GENERATE NOVEL RESOURCES, INCLUDING STROMAL CELL LINES, REPORTER MICE, IMAGING TECHNOLOGY, AND ASSAYS TO QUANTIFY THE EXTENT OF RENAL REPLACEMENT BY ORGANOID TISSUE. WE PROPOSE THE FOLLOWING AIMS: AIM 1: DEVELOP STRATEGIES TO MODULATE ORGANOID STROMA TO PROMOTE PROXIMAL NEPHRON SEGMENTS 1A. DEVELOP PROTOCOLS TO PROMOTE FORMATION OF PROXIMAL TUBULE STROMA. 1B. INVESTIGATE THE ROLE OF MACROPHAGES IN ORGANOID DIFFERENTIATION. AIM 2. GENERATE ROBUST AND FUNCTIONALLY REGIONALIZED RENAL VASCULATURE IN TISSUE GRAFTS 2A. EVALUATE VASCULAR MAINTENANCE, GROWTH, AND RECRUITMENT IN ORGANOIDS. 2B. CHARACTERIZE STROMAL IMPACT ON ORGANOID VASCULATURE. 2C. GENERATE “VASCULAR-PRIMED” ORGANOIDS. AIM 3. IDENTIFY STRATEGIES TO PROMOTE TUBULE FUSION IN RENAL EPITHELIA 3A. IDENTIFY THE ROLE OF STROMAL INTERACTIONS ON EPITHELIAL TUBULE ANASTOMOSIS. 3B. DETERMINE THE ROLE OF HGF AND TGFSS ON TUBULE ANASTOMOSIS IN ORGANOIDS. AIM 4. EVALUATE FUNCTION OF GRAFT TISS
Department of Health and Human Services
$7M
APPLICATION OF PROGENITOR NICHE SIGNALS TO EX VIVO NEPHROGENESIS
Department of Defense
$553K
MODELING THE EFFECTS OF STROMA ON CLEAR CELL RENAL CELL CARCINOMA
Source: Federal Audit Clearinghouse (fac.gov)
Total Audits
5
Clean Audits
2
Material Weakness
Yes
Noncompliance Issues
No
| Year | Status | Financial Report | Federal Expenditure | Low Risk | Accepted |
|---|---|---|---|---|---|
| 2024 | Clean | Unmodified (Clean) | $2.4M | No | 2025-09-15 |
| 2023 | Clean | Unmodified (Clean) | $2.1M | No | 2024-09-27 |
| 2022 | Material Weakness | Unmodified (Clean) | $2.2M | No | 2023-09-28 |
| 2021 | Material Weakness | Unmodified (Clean) | $3.5M | No | 2022-09-28 |
| 2020 | Material Weakness | Unmodified (Clean) | $958.3K | No | 2022-03-06 |
Financial Report
Unmodified (Clean)
Federal Expenditure
$2.4M
Financial Report
Unmodified (Clean)
Federal Expenditure
$2.1M
Financial Report
Unmodified (Clean)
Federal Expenditure
$2.2M
Financial Report
Unmodified (Clean)
Federal Expenditure
$3.5M
Financial Report
Unmodified (Clean)
Federal Expenditure
$958.3K
Tax Year 2024 · Source: IRS e-Filed Form 990Schedule J available
Individuals serving as officers, directors, or trustees of the organization.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other |
|---|
Source: IRS Publication 78, Auto-Revocation List & e-Postcard Data
Tax-deductible contributions: Yes
Deductibility code: PC
Sources: IRS e-Filed Form 990 (XML) & ProPublica Nonprofit Explorer
Scroll →
| Year | Revenue | Contributions | Expenses | Assets | Net Assets |
|---|---|---|---|---|---|
| 2024IRS e-File | $122.8M | $5M | $122M | $111.8M | $16.6M |
| 2023IRS e-File | $118.4M | $4.3M | $122.7M | $116.8M | $16M |
| 2022 | $116.5M | $5.3M | $123.9M | $117.9M | $6.8M |
| 2021 | $118.1M |
Sources: ProPublica Nonprofit Explorer & IRS e-File Index
| Tax Year | Form Type | Source | Documents |
|---|---|---|---|
| 2024 | 990 | IRS e-File | PDF not yet published by IRSView Filing → |
| 2023 | 990 | DataIRS e-File | PDF not yet published by IRSView Filing → |
| 2022 | 990 | DataIRS e-File |
Financial data: IRS e-Filed Form 990 (Tax Year 2024)
Leadership & compensation: IRS e-Filed Form 990, Part VII (Tax Year 2024)
Federal grants: USAspending.gov (live)
Organization info: IRS Business Master File
Tax-deductibility: IRS Publication 78
| Total |
|---|
| Shaun E Smith | Secretary | 1 | $0 | $1.9M | $63.5K | $2M |
| Karen Westervelt | Vice Chair | 1 | $0 | $1.5M | $70.9K | $1.6M |
| Miriam Rike | Treasurer | 1 | $0 | $1.3M | $75.2K | $1.4M |
| David Wyman | President | 58 | $0 | $868.3K | $53.3K | $921.6K |
| Stuart D Saal | VP Nephrology/consultive Svcs | 60 | $601.3K | $0 | $57K | $658.3K |
| Jeffrey Silberzweig | VP Nephrology/dialysis & Cmo | 60 | $497.1K | $0 | $22.7K | $519.8K |
| Allyson Z Pifko | Evp/coo | 60 | $452.4K | $0 | $25.1K | $477.6K |
| Daniel M Levine | VP Info. Tech./cio | 60 | $351.6K | $0 | $47.2K | $398.8K |
| Bruce R Gordon | Evp/clinical Service & Strategy (thru 3/2024) | 60 | $124K | $0 | $8,834 | $132.8K |
| Robert Min | Chariman | 5 | $0 | $0 | $0 | $0 |
Shaun E Smith
Secretary
$2M
Hrs/Wk
1
Compensation
$0
Related Orgs
$1.9M
Other
$63.5K
Karen Westervelt
Vice Chair
$1.6M
Hrs/Wk
1
Compensation
$0
Related Orgs
$1.5M
Other
$70.9K
Miriam Rike
Treasurer
$1.4M
Hrs/Wk
1
Compensation
$0
Related Orgs
$1.3M
Other
$75.2K
David Wyman
President
$921.6K
Hrs/Wk
58
Compensation
$0
Related Orgs
$868.3K
Other
$53.3K
Stuart D Saal
VP Nephrology/consultive Svcs
$658.3K
Hrs/Wk
60
Compensation
$601.3K
Related Orgs
$0
Other
$57K
Jeffrey Silberzweig
VP Nephrology/dialysis & Cmo
$519.8K
Hrs/Wk
60
Compensation
$497.1K
Related Orgs
$0
Other
$22.7K
Allyson Z Pifko
Evp/coo
$477.6K
Hrs/Wk
60
Compensation
$452.4K
Related Orgs
$0
Other
$25.1K
Daniel M Levine
VP Info. Tech./cio
$398.8K
Hrs/Wk
60
Compensation
$351.6K
Related Orgs
$0
Other
$47.2K
Bruce R Gordon
Evp/clinical Service & Strategy (thru 3/2024)
$132.8K
Hrs/Wk
60
Compensation
$124K
Related Orgs
$0
Other
$8,834
Robert Min
Chariman
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Highest compensated employees who are not officers or directors.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other | Total |
|---|---|---|---|---|---|---|
| Jun B Lee | Physician | 39 | $479.7K | $76.6K | $56.5K | $612.8K |
| Alan S Perlman | Physician | 35 | $455.3K | $0 | $62K | $517.3K |
| Andrew Bohmart | Physician | 35 | $494.3K | $0 | $20.1K | $514.5K |
Jun B Lee
Physician
$612.8K
Hrs/Wk
39
Compensation
$479.7K
Related Orgs
$76.6K
Other
$56.5K
Alan S Perlman
Physician
$517.3K
Hrs/Wk
35
Compensation
$455.3K
Related Orgs
$0
Other
$62K
Andrew Bohmart
Physician
$514.5K
Hrs/Wk
35
Compensation
$494.3K
Related Orgs
$0
Other
$20.1K
Members of the governing board. Board members often serve without compensation.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other | Total |
|---|---|---|---|---|---|---|
| Anne Alexis Cote Taylor | Director (thru 6/2024) | 1 | $0 | $0 | $0 | $0 |
| Brian K Regan | Director | 1 | $0 | $563.3K | $87.8K | $651K |
| Charlotte M Ford | Director | 1 | $0 | $0 | $0 | $0 |
| Claudia Rosen | Director | 1 | $0 | $974.6K |
Anne Alexis Cote Taylor
Director (thru 6/2024)
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Brian K Regan
Director
$651K
Hrs/Wk
1
Compensation
$0
Related Orgs
$563.3K
Other
$87.8K
Charlotte M Ford
Director
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Individuals who previously served as officers or key employees.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other | Total |
|---|---|---|---|---|---|---|
| Rex A Friedlander | Former Key Employee | 35 | $240.4K | $0 | $11.6K | $252K |
Rex A Friedlander
Former Key Employee
$252K
Hrs/Wk
35
Compensation
$240.4K
Related Orgs
$0
Other
$11.6K
| $6.3M |
| $119.7M |
| $82.5M |
| $18.5M |
| 2020 | $114.2M | $3.5M | $118.8M | $90.4M | $20.4M |
| 2019 | $110.9M | $2M | $114.2M | $84M | $28.3M |
| 2018 | $102M | $2.2M | $105.7M | $81.1M | $30.9M |
| 2017 | $99.4M | $7.5M | $101.2M | $81.1M | $35.7M |
| 2016 | $91.9M | $3.1M | $95.4M | $73.7M | $36.2M |
| 2015 | $96M | $4.9M | $95.5M | $77.8M | $39.7M |
| 2014 | $100.1M | $9.7M | $88.9M | $72.3M | $39.9M |
| 2013 | $73M | $4.7M | $69.2M | $58.3M | $29.4M |
| 2012 | $71.9M | $4.2M | $67.4M | $53.4M | $24.6M |
| 2011 | $64.1M | $3.4M | $66.2M | $46.6M | $19.9M |
| 2021 | 990 | Data |
| 2020 | 990 | Data |
| 2019 | 990 | Data |
| 2018 | 990 | Data |
| 2017 | 990 | Data | PDF not yet published by IRS |
| 2016 | 990 | Data |
| 2015 | 990 | Data |
| 2014 | 990 | Data |
| 2013 | 990 | Data |
| 2012 | 990 | Data |
| 2011 | 990 | Data |
| 2010 | 990 | — |
| 2009 | 990 | — |
| 2008 | 990 | — |
| 2007 | 990 | — |
| 2006 | 990 | — |
| 2005 | 990 | — |
| 2004 | 990 | — |
| 2003 | 990 | — |
| 2002 | 990 | — |
| 2001 | 990 | — |
| Vijay K Sharma | Lab Director | 35 | $438.3K | $0 | $37K | $475.2K |
| Jay Lakkis | Physician | 35 | $430.9K | $0 | $34.4K | $465.3K |
| Frank Liu | Physician | 35 | $426.6K | $0 | $23.4K | $450.1K |
| Diana Decolongon | Hr Director | 35 | $214.3K | $0 | $22.6K | $236.9K |
Vijay K Sharma
Lab Director
$475.2K
Hrs/Wk
35
Compensation
$438.3K
Related Orgs
$0
Other
$37K
Jay Lakkis
Physician
$465.3K
Hrs/Wk
35
Compensation
$430.9K
Related Orgs
$0
Other
$34.4K
Frank Liu
Physician
$450.1K
Hrs/Wk
35
Compensation
$426.6K
Related Orgs
$0
Other
$23.4K
Diana Decolongon
Hr Director
$236.9K
Hrs/Wk
35
Compensation
$214.3K
Related Orgs
$0
Other
$22.6K
| $50.5K |
| $1M |
| Fred H Mermelstein | Director | 1 | $0 | $0 | $0 | $0 |
| James Perkins | Director | 1 | $0 | $0 | $0 | $0 |
| Jennings R Aske | Director | 1 | $0 | $991.7K | $79.5K | $1.1M |
| John Cl Wang | Director | 1 | $0 | $0 | $0 | $0 |
| Juan Mejia | Director | 1 | $0 | $1.2M | $85.7K | $1.3M |
| Kurt H Stenzel | Director (thru 4/2024) | 5 | $0 | $0 | $0 | $0 |
| Michael G Stewart | Director | 1 | $0 | $0 | $0 | $0 |
| Nazim B Malatyali | Director | 1 | $0 | $947.7K | $87.6K | $1M |
| Richard Evans | Director | 1 | $0 | $1.1M | $87.4K | $1.2M |
| Robert Fried | Director | 1 | $0 | $0 | $0 | $0 |
| Wilhelmina Manzano | Director | 1 | $0 | $2.2M | $203.3K | $2.4M |
| Zeynep Sumer-King | Director | 1 | $0 | $507.9K | $66.4K | $574.2K |
Claudia Rosen
Director
$1M
Hrs/Wk
1
Compensation
$0
Related Orgs
$974.6K
Other
$50.5K
Fred H Mermelstein
Director
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
James Perkins
Director
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Jennings R Aske
Director
$1.1M
Hrs/Wk
1
Compensation
$0
Related Orgs
$991.7K
Other
$79.5K
John Cl Wang
Director
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Juan Mejia
Director
$1.3M
Hrs/Wk
1
Compensation
$0
Related Orgs
$1.2M
Other
$85.7K
Kurt H Stenzel
Director (thru 4/2024)
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Michael G Stewart
Director
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Nazim B Malatyali
Director
$1M
Hrs/Wk
1
Compensation
$0
Related Orgs
$947.7K
Other
$87.6K
Richard Evans
Director
$1.2M
Hrs/Wk
1
Compensation
$0
Related Orgs
$1.1M
Other
$87.4K
Robert Fried
Director
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Wilhelmina Manzano
Director
$2.4M
Hrs/Wk
1
Compensation
$0
Related Orgs
$2.2M
Other
$203.3K
Zeynep Sumer-King
Director
$574.2K
Hrs/Wk
1
Compensation
$0
Related Orgs
$507.9K
Other
$66.4K